Routes ofadministration By mouth (tablets) Bioavailability Not determined Molar mass 894.11 g/mol | Legal status US: ℞-only Protein binding ~99.9% | |
 | ||
Trade names Viekira Pak, Viekira XR (with ombitasvir, paritaprevir, ritonavir and dasabuvir),Technivie (with ombitasvir, paritaprevir, and ritonavir) Metabolism | ||
3d drug consultation webinar ombitasvir paritaprevir ritonavir dasabuvir part 1
Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1, and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4.
Contents
- 3d drug consultation webinar ombitasvir paritaprevir ritonavir dasabuvir part 1
- 3d drug consultation webinar ombitasvir paritaprevir ritonavir dasabuvir part 2
- References
Ombitasvir is an NS5A inhibitor that acts by inhibiting the HCV protein NS5A.
3d drug consultation webinar ombitasvir paritaprevir ritonavir dasabuvir part 2
References
Ombitasvir Wikipedia(Text) CC BY-SA